Type II Variation [Regulatives / Guidelines]

posted by Ohlbe – France, 2013-09-18 14:41 (4661 d 23:30 ago) – Posting: # 11517
Views: 6,265

Dear all,

❝ A new BE must not be mandatory.


Well... I've heard of some dossiers where the French Agency made it a clear condition when granting a marketing authorisation.

Regulators are not too happy with applicants who think a little too obviously that they are stupid :-D. If you run your BE with a batch of 50,000 tablets and claim this will be your full industrial batch size, then come with a variation to increase the size to 500,000 without a new BE, you can expect some difficulties.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
117 visitors (0 registered, 117 guests [including 13 identified bots]).
Forum time: 14:11 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5